C4 Therapeutics, Inc.

Contributing Author

Recent Articles by C4 Therapeutics, Inc.

Nov-06	C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Oct-16	C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering CCCC GlobeNewswire
Oct-01	C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma CCCC GlobeNewswire
Sep-20	C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting CCCC GlobeNewswire
Sep-04	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration CCCC GlobeNewswire
Sep-03	C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Aug-07	C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
May-07	C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire